Nicole Germino
Stock Analyst at Truist Securities
(4.55)
# 330
Out of 4,876 analysts
24
Total ratings
65%
Success rate
21.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $18 → $14 | $4.70 | +197.87% | 3 | May 14, 2025 | |
| CATX Perspective Therapeutics | Maintains: Buy | $10 → $8 | $3.76 | +112.77% | 3 | May 14, 2025 | |
| INSM Insmed | Maintains: Buy | $105 → $108 | $99.49 | +8.55% | 8 | Feb 21, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.54 | +824.39% | 5 | Jan 23, 2025 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $17.21 | +39.45% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $12.25 | - | 2 | Sep 3, 2021 |
Y-mAbs Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $4.70
Upside: +197.87%
Perspective Therapeutics
May 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.76
Upside: +112.77%
Insmed
Feb 21, 2025
Maintains: Buy
Price Target: $105 → $108
Current: $99.49
Upside: +8.55%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.54
Upside: +824.39%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $17.21
Upside: +39.45%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $12.25
Upside: -